Tuesday , December 12 2017
Home / Letter From The Editor / GLP-1 Editor’s Note:

GLP-1 Editor’s Note:

This week I had a chance to interview Dr. Vivian Fonseca on the use of GLP-1 agonists, and he shared his thoughts on why these medications are a logical choice. He also gave us a little information on a study using GLP-1 agonists with insulin, and why he thinks the FDA should approve the combination.

Our GLP-1 Case Study this week targets a 25-year-old Hispanic woman with a 5-year history of type 2 diabetes, who has not been able to get her A1c under control, and Louis Kuritzky, MD, Clinical Assistant Professor, University of Florida, has a short interactive video on the potential for tissue damage before and after diagnosis of diabetes, and the protective benefits of early and effective intervention.